Par Pharmaceutical: An AndroGel Challenger’s Deal to Promote the Brand

The Par Pharmaceutical AndroGel antitrust case concerned an alleged pay-for-delay agreement in which Solvay promised Par $60 million, although Par had filed no generic application of its own. Par had joined Paddock’s challenge to the brand, sharing the patent litigation costs in return for a stake in future generic profits. The settlement gave Par a different job: promoting the branded AndroGel it had planned to help compete against.

The Federal Trade Commission alleged that Solvay’s payments bought delayed generic competition. The companies said they were paying for services. As in other pharmaceutical fraud cases, the business question sits in the contracts: what work did the money buy, and what happened to the plan to launch a competing drug?

Par Joined Paddock Without Its Own Application

Par entered the AndroGel dispute through a partnership with Paddock Laboratories. The Supreme Court’s account distinguishes Par from both manufacturers that filed generic applications: Watson Pharmaceuticals, later known as Actavis, filed first, and Paddock filed separately afterward.

AndroGel was Solvay’s branded testosterone replacement gel. Watson and Paddock challenged Solvay’s patent, asserting that it was invalid and that their proposed generics did not infringe it. Par agreed to share Paddock’s patent litigation costs for a share of profits if Paddock won approval. Par also agreed to sell Paddock’s generic product. Paddock later assigned its rights in that product to Par.

That arrangement gave Par an economic stake in the challenge without requiring an application under Par’s own name. Paddock supplied the application and proposed generic product. Par supplied cost sharing and a route to sales. Reading only the applicant’s name would miss the commercial partner with money riding on the result.

Why the Generic Application Mattered

The patent challenge changes the timing. Under the paragraph IV route described in the Supreme Court opinion, a generic applicant says the listed patent is invalid or will not be infringed. A timely patent lawsuit ordinarily holds up FDA approval for 30 months while the dispute proceeds. The first applicant can also obtain 180 days of generic exclusivity after its commercial launch.

Those incentives explain the different positions at the bargaining table. Watson was the first filer. Paddock had its own application. Par’s opportunity depended on the Paddock partnership. The Federal Trade Commission later challenged agreements that brought all of those interests into a settlement with Solvay.

What the AndroGel Agreement Gave Par

The settlement paired Par’s promise to delay generic entry with an agreement to promote Solvay’s brand. In its account of the business terms, the district court described Solvay sharing AndroGel profits with Par while Par promoted the drug to primary care physicians. Paddock separately agreed to serve as a backup supplier.

By the time the parties settled in 2006, the FDA had approved Actavis’s generic and the challengers were waiting for the judge to rule on their attack on the patent’s validity. The settlement put an end to that challenge.

Par and Paddock’s entry schedule centered on August 31, 2015, subject to first-filer exclusivity, with earlier entry if another company launched a generic. Solvay estimated annual payments of about $6 million to Par and about $2 million to Paddock.

The Supreme Court put Solvay’s separate commitment to Paddock at $12 million in total. Actavis also agreed to promote AndroGel, to urologists. The brand company had arranged for prospective competitors to help sell or supply its existing product.

The companies described the payments as compensation for those services. The Federal Trade Commission alleged that the services had little value and that the money’s real purpose was to compensate the generic companies for staying out of AndroGel’s market. That disagreement makes the work behind a promotion or supply contract central to the case.

Why the Supreme Court Reopened Antitrust Review

The Supreme Court ruled on June 17, 2013 that the Federal Trade Commission had to be allowed to prove its antitrust claim. It overturned the dismissal and sent the case back for review of the settlement’s competitive effects.

The earlier approach had largely shielded a settlement if its restrictions stayed within what the patent could have blocked. But the patent itself was under challenge. The Court explained the economic problem: a brand manufacturer can share the profits from keeping prices high with the challenger that might otherwise bring those prices down. Both companies gain from the payment while people buying the drug keep paying the brand’s price.

The Court required a fact-specific review. That meant examining the payment’s size, how it compared with expected litigation costs, whether other services explained it, and any other convincing justification. The ruling opened that examination and left the Federal Trade Commission to prove its case.

The Consent Judgment Left Out the Business Agreements

Par, Paddock and Solvay then argued that the court’s consent judgment protected their settlement from antitrust review. The district court rejected that argument in its April 18, 2014 order because the judgment did not contain the full bargain.

The court said the profit-sharing and business promotion agreements had never been disclosed to it and were absent from the judgment the parties submitted. Its description of its own earlier role was unusually direct:

The companies sought protection from a court signature on a document that left out the payments at the center of the FTC’s challenge. The settlement, co-promotion and backup-manufacturing agreements together supplied the business terms the court had to examine.

The order drew a parallel with an earlier Cipro dispute involving Bayer and Barr. Their two-page consent judgment omitted Bayer’s payment to Barr and its agreements with other generic competitors. The court in that dispute likewise refused to let the signed judgment shield the private agreements from antitrust review. The point travels beyond AndroGel: the document ending the patent case may leave out the contracts that explain the money.

Generic Settlements Continued, but Payment Terms Changed

The industry kept settling patent disputes after the Supreme Court ruling. A 2018 Public Citizen report on pharmaceutical industry penalties reported Federal Trade Commission figures showing potential pay-for-delay deals falling from 40 in fiscal 2012 to 14 in fiscal 2015.

That category counted agreements combining explicit compensation with a restriction on generic entry. The Federal Trade Commission’s filed-agreement series shows that total settlements increased over those years. The distinction matters to someone who negotiates these deals: the business value exchanged alongside the entry date is what makes a settlement worth examining.

The Contract Money and the Government’s Money

The AndroGel amounts described here were Solvay’s private payment commitments to generic-side companies. The Federal Trade Commission brought an antitrust action over those arrangements. A separate question for pharmaceutical whistleblowers is whether their knowledge also reveals false claims or false price reports affecting a government program.

False manufacturer price reports can change what public programs pay or collect in rebates. In government price reporting, calling a discount a service fee can leave Medicare Part B paying too much. Treating a real service fee as a discount can lower what a manufacturer owes Medicaid. An insider who knows what a contract actually bought may also know whether the company reported that payment truthfully.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Contracts Bought

If you worked on a generic partnership, promotion contract or launch restriction, speak to one of our whistleblower experts about what the agreement really bought. We examine the business terms with you, assess any connection to false government payments, and bring in pharmaceutical whistleblower lawyers with the expertise your case needs. We stay beside you as partners through the case.